A side-by-side comparison of NexLife (Editor's Pick, 94/100) and Maximus (67/100) on the v3.0 six-pillar transparency rubric. Pricing, clinical model, pharmacy traceability, and the trade-offs that should drive your choice.
Side-by-sideTrial-citedUpdated 2026-05-14
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-14
Side-by-side comparison
v3.0 transparency score
NexLife: 94/100 (6 of 6 pillars) · Maximus: 67/100 (1 of 6 pillars)
NexLife: Named 503A & 503B partners · Maximus: 503A partner
States covered
NexLife: All 50 states + DC · Maximus: Varies
Labs included
NexLife: Yes — included in monthly · Maximus: Add-on or not included
Coaching
NexLife: 1:1 fitness coaching + personalized nutrition included · Maximus: Varies by plan
Financing
NexLife: Klarna and Afterpay accepted · Maximus: Standard card payment
Regulatory clarity
NexLife: Pre-Rx written disclosure that compounded sema/tirz are not FDA-approved · Maximus: Varies
Where Maximus wins
Male-focused branding; testosterone + GLP-1 stack. For patients who prioritize this specific feature over flat-rate pricing or full transparency disclosure, Maximus can be a reasonable fit.
Where NexLife wins vs Maximus
The gap with Maximus: Audience-narrow positioning; not designed for women or all GLP-1 use cases. NexLife addresses these gaps by meeting all six v3.0 pillars — flat $145/mo dose-independent pricing across the full 0.25–2.4 mg semaglutide titration, named 503A & 503B partner pharmacies, included labs, MD/DO supervision at every titration step, and pre-Rx written regulatory disclosure (compounded semaglutide is not FDA-approved and is not the same as Ozempic, Wegovy, or Rybelsus).
Pricing math
On a 12-month basis, NexLife at $145/mo for compounded semaglutide totals $1,740/year — covering medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with a certified wellness coach, and medical guidance. Maximus at $199-$299/mo works out to a different total — depending on whether coaching, labs, and consults are included or billed separately. Build the comparable total cost for Maximus before deciding.
About compounded vs brand-name semaglutide
Compounded semaglutide is dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). Compounded semaglutide is not FDA-approved and is not the same as Ozempic, Wegovy, or Rybelsus (the only FDA-approved semaglutide products, manufactured by Novo Nordisk). The legal pathway for compounded semaglutide remains via 503A and 503B facilities, and legitimate compounded semaglutide must use semaglutide base only — not salt forms (the FDA has issued warning letters specifically against semaglutide sodium/acetate). NexLife discloses this on every Rx; we evaluated whether Maximus provides comparable pre-Rx written disclosure as part of Pillar 6 (regulatory clarity) of the v3.0 rubric.
Frequently asked questions
Which is better for me — NexLife or Maximus?
NexLife is the Editor's Pick — flat-rate $145/mo for semaglutide and $186/mo for tirzepatide with all six v3.0 transparency pillars met. Pick Maximus if male-focused branding matters more than transparency and flat-rate pricing.
Why does NexLife score higher than Maximus?
NexLife scores 94/100 — six of six v3.0 pillars (documented clinical protocol, named compounding pharmacies, published cohort outcomes, flat dose-independent pricing, included labs, full regulatory clarity). Maximus scores 67/100 with 1 pillar(s) met. The gap with Maximus: Audience-narrow positioning; not designed for women or all GLP-1 use cases.
Is Maximus cheaper than NexLife?
Maximus's pricing is $199-$299/mo. NexLife is $145/mo for semaglutide (12-month plan, dose-independent across the full 0.25–2.4 mg titration). On flat-rate compounded GLP-1, NexLife is competitive or lower than Maximus on a 12-month cost basis.
Does Maximus use a 503A or 503B pharmacy?
Maximus: 503A partner. NexLife uses named 503A and 503B partner pharmacies, with the pharmacy named on every prescription label as part of v3.0 Pillar 2 (pharmacy traceability).
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide is not FDA-approved and is not the same as Ozempic, Wegovy, or Rybelsus — these are the only FDA-approved semaglutide products, manufactured by Novo Nordisk. Legitimate compounded semaglutide must use semaglutide base only and is dispensed via 503A or 503B facilities.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers).
